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Abstract
The use of topical and oral adenosine derivatives in HIV prevention that need to be maintained in tissues and cells at
effective levels to prevent transmission prompted us to ask whether estradiol could influence the regulation of catabolic
nucleotidase enzymes in epithelial cells and fibroblasts from the upper and lower female reproductive tract (FRT) as these
might affect cellular TFV-DP levels. Epithelial cells and fibroblasts were isolated from endometrium (EM), endocervix (CX)
and ectocervix (ECX) tissues from hysterectomy patients, grown to confluence and treated with or without estradiol prior to
RNA isolation. The expression of nucleotidase (NT) genes was measurable by RT-PCR in epithelial cells and fibroblasts from
all FRT tissues. To determine if sex hormones have the potential to regulate NT, we evaluated NT gene expression and NT
biological activity in FRT cells following hormone treatment. Estradiol increased expression of Cytosolic 59-nucleotidase after
2 or 4 h in endometrial epithelial cells but not epithelial cells or fibroblasts from other sites. In studies using a modified 59-
Nucleotidase biological assay for nucleotidases, estradiol increased NT activity in epithelial cells and fibroblasts from the EM,
CX and ECX at 24 and 48 h. In related studies, HUVEC primary cells and a HUVEC cell line were unresponsive to estradiol in
terms of nucleotidase expression or biological activity. Our findings of an increase in nucleotidase expression and biological
activity induced by estradiol do not directly assess changes in microbicide metabolism. However, they do suggest that
when estradiol levels are elevated during the menstrual cycle, FRT epithelial cells and fibroblasts from the EM, CX and ECX
have the potential to influence microbicide levels that could enhance protection of HIV-target cells (CD4+T cells,
macrophages and dendritic cells) throughout the FRT.
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Introduction
Thirty years into the Human Immunodeficiency Virus (HIV)
global pandemic, more than 30 million people have died with an
additional 33 million presently living with HIV [1,2]. Worldwide,
approximately 70% of all new cases are spread by sexual
intercourse, with women more likely to be infected than men
[3]. Vaginal and anal sexual intercourse are the primary sources of
infection in women, with adolescent age, sexual violence, and co-
infection with sexually transmitted diseases (STDs) among the risk
factors that contribute to enhanced susceptibility to HIV infection
[2,4].
With no effective vaccine available, attention has been focused
on the use of anti-retroviral drugs to prevent infection (Pre-
exposure Prophylaxis (PrEP)). For example, the nucleoside-analog
reverse transcriptase inhibitor (NRTI) tenofovir demonstrated
efficacy in in vitro studies, animal models and initial clinical trials
[5,6]. When delivered orally, tenofovir (TFV) accumulated in
rectal tissue at a 33-fold higher concentration than in plasma, thus
having the potential to inhibit the establishment of a founder
population of infected cells at the site of HIV introduction during
anal sex [5]. Topical application of microbicide gels to the GI and
genital mucosa specific sites has also been effective in reducing
infection. For example, the Centre for the AIDS Programme of
Research in South Africa (CAPRISA 004, a phase IIb study),
demonstrated a 39% efficacy of the Tenofovir gel used vaginally
before and after sex in reducing the risk of HIV acquisition among
women [7]. However, in direct contrast, the use of oral TFV and
TFV as a vaginal gel in the Vaginal and Oral Interventions to
Control the Epidemic (VOICE) trial [8] failed to protect women
against the sexual acquisition of HIV. As a result, both oral and
vaginal TFV arms of the VOICE trial were terminated [9] and
subsequent analysis revealed a serious lack of adherence [10].
While adherence in trials is critical to evaluating success or failure,
other factors such as hormonal status and existing STI may
contribute as well.
The FRT is the primary mucosal site of infection by STDs
including HIV. The FRT mucosa is composed of multiple cell
types including epithelial cells, fibroblasts and immune cells. They
all play a central role in providing cellular, humoral, and innate
immune protection against bacterial and viral invasion [11,12].
Previously, we found that FRT epithelial cells and fibroblasts were
capable of both mounting an immune response and modulating
immune cell function [13–18]. In addition, the secretion of
immune factors by these FRT cells is under hormonal control [13–
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e69854
18]. Acting directly via hormone receptors and indirectly through
cytokines, chemokines, and growth factors, estradiol and proges-
terone selectively enhance and suppress elements of the immune
system during the menstrual cycle to optimize conditions for
reproductive success [19]. By inhibiting immune responses to
sperm and a non-syngeneic fetus during the secretory phase of the
menstrual cycle, the chances for conceptus/fetus survival is
increased. These changes led to the hypothesis of a ‘‘Window of
Vulnerability’’ in the FRT, when HIV and other sexually
transmitted pathogens are most likely to infect women [19].
Evidence (proof of concept) for the ‘‘Window’’ has been reported
in a recent study with macaques. Using repeated, low dose
SHIVSF162P3 vaginal exposures during normal menstrual cycles,
18 macaques (95%) first displayed viremia in the follicular phase
compared with 1 macaque (5%) in the luteal phase. Taking into
account a viral eclipse of 7–14 days before viremia could be
detected, Vishwanathan et.al. estimated a ‘‘window’’ of most
frequent viral transmission between days 24 and 32 of the
menstrual cycle, when progesterone levels are high [20].
Tenofovir is an acyclic nucleotide analogue that is active only
after entering target cells, where it is phosphorylated to TFV-
diphosphate (TFV-DP) [21]. TFV-DP is a nucleotide reverse
transcriptase inhibitor (NRTI) that causes chain termination of the
growing DNA molecule. 59-Nucleotidases are a class of enzymes
involved in the catabolism of nucleotides through dephosphory-
lation of nucleotide terminal phosphate with a preference for
nucleotide monophosphates [22]. These enzymes regulate the
activation of the nucleotide analogs such as TFV, which need
nucleotide kinases for phosphorylation to their active form. Several
studies have demonstrated that nucleotidases are present in
epithelial cells in the rodent FRT [23] and that nucleotidase
mRNA levels are highest at estrus, the stage of the reproductive
cycle when estrogens are elevated [24]. However, expression
patterns and hormonal regulation of human nucleotidases in the
FRT are unknown. Others have demonstrated that nucleotidases
are present in vascular endothelial cells [25]. In human studies,
breast cancer cell nucleotidase levels were higher in tumors lacking
estrogen receptors (ER) than in tumors that were ER positive and
known to be estradiol responsive [26].
Figure 1. Relative gene expression of nucleotidases in FRT epithelial cells. Data is shown as the ratio of the nucleotidase (NT) gene
expression to the expression of b-actin. Purified cultures of (A) FT n= 3, (B) EM n=8, (C) CX n= 8 and (D) ECX n= 10 epithelial cells were analyzed for
changes in nucleotidase gene expression by RT-PCR. n refers to the number of patients for each tissue. 59-Nucleotidases measured were Ecto-59-
nucleotidase (NT5E), Cytosolic 59-nucleotidase 1A (NT5C1A), Cytosolic 59-nucleotidase 1B (NT5C1B), Cytosolic 59-nucleotidase II (NT5C2), Cytosolic 59-
nucleotidase III (NT5C3L), Cytosolic 59(39)-deoxyribonucleotidase (NT5C), and Mitochondrial 59(39)-deoxyribonucleotidase (NT5M). UD=undetectable.
The mean and SEM are shown.
doi:10.1371/journal.pone.0069854.g001
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The 59-nucleotidases catalyze dephosphorylation of nucleotides
with a preference for monophosphates and play a role in the
regulation of nucleotide and nucleoside levels in all cells. These
enzymes are of clinical interest due to their ability to inactivate of
nucleoside analog drugs that are used in anticancer and antiviral
drug therapy [27–29]. The 59-nucleotidases vary in substrate
specificity and tissue expression. For example, NT5E (CD73, 59-
ecto-nucleotidase), the most studied of this family of 59-nucleotid-
ases, catalyzes the conversion of purine 59-mononucleotides such
as AMP to nucleosides, is bound to the external surface of the
plasma membrane in most tissues and has broad effects in cellular
function, including cell attachment and transport of molecules into
the cell (for review, see [22]). In addition, other forms of 59-
nucleotidases exist in the cytoplasm (C, such as NT5C1A) and
mitochondria (M, such as NT5M).
Previous studies have demonstrated that the Organic Anion
Transporter (OAT) proteins OAT1 and 3 are capable of
transporting tenofovir into the cells lining the kidney proximal
tubule and that specific members of the Multi-Drug Resistance
Protein (MRP) transporter family can move tenofovir out of the
cell and into the extracellular space [30,31]. Others have shown
that endothelial cells express OAT1 and OAT3 receptors and that
androgen receptors in the brain are involved in the functional
regulation of OAT3 at the blood brain barrier [32]. OAT1 and
OAT3 receptors, known to transport TFV, are present in the
rodent uterus [33] and thought to be under estrogen control based
on gender differences in the kidney proximal tubule [34,35].
Kohler and colleagues found that OAT1 and MRP4 have a direct
role in transport and efflux of TFV, regulating levels in proximal
tubules of the kidney [36].
Based on these findings, we hypothesized that estradiol has the
potential to affect tenofovir efficacy by influencing NT expression
and biological activity of epithelial cells, fibroblasts and endothelial
cells in the human FRT. Our rationale for these studies is based on
the recognition that to reach HIV-target cells imbedded in the
stroma of the FRT, TFV taken orally must permeate endothelial
cells to enter the FRT stroma, or in the case of vaginal deposition,
move through and/or between epithelial cells, and fibroblasts to
reach HIV-target cells (CD4+Tcells, macrophages and dendritic
cells) in the upper and lower FRT [6]. The goal of this study was to
determine whether estradiol and progesterone regulate the
expression of transport receptors and 59-nucleotidase enzyme
expression and biological activity in epithelial cells and stromal
fibroblasts throughout the FRT.
Materials and Methods
Source of Tissue
Human female reproductive tract tissues were obtained
immediately following surgery from women who had undergone
hysterectomies at Dartmouth-Hitchcock Medical Center (Leba-
non, NH). All tissues used in this study, including Fallopian tube
(FT), endometrium (EM), endocervical (CX), and ectocervical
(ECX) tissues, were collected from patients with benign conditions
such as fibroids and prolapse. Tissue samples were distal from the
sites of pathology and were without pathological lesions as
determined by a pathologist. All human subject work was carried
out with the approval of the Dartmouth College Institutional
review Board. Approval to use tissues was previously obtained
from the Committee for the Protection of Human Subjects
(CPHS), and with written informed consent obtained from the
patient before surgery.
Isolation of FRT Epithelial Cells and Fibroblasts
Epithelial cells and stromal fibroblasts from the FT, EM, CX
and ECX were isolated as previously described [14,37]. Briefly,
tissues were rinsed with 16 HBSS with phenol red, containing
100 U/ml penicillin, 100 mg/ml streptomycin (all Thermo Scien-
tific Hyclone, Logan, UT), and 0.35 mg/ml NaCO3 (Fisher
Scientific, Pittsburgh, PA), then minced under sterile conditions
into 1–2 mm fragments and digested at 37uC for 1 h using an
enzyme mixture containing (final concentrations): 3.4 mg/ml
pancreatin, 0.1 mg/ml hyaluronidase (both from Sigma, St. Louis,
MO), 1.6 mg/ml collagenase D (Roche, Indianapolis, IN), and
2 mg/ml D-glucose (EMD, Gibbstown, NJ) in 16HBSS (Invitro-
gen Life Technologies). Enzymes were chosen to maximize
digestion of the extracellular matrix, as verified by microscopy of
hematoxylin and eosin-stained frozen sections after digestion.
After digestion, cells were dispersed through a 250-mm nylon mesh
screen (Small Parts, Miami Lakes, FL), washed, and resuspended
in complete media consisting of DMEM/F12 medium without
phenol red, supplemented with 10 mM HEPES (both GIBCO,
Life Technologies, Grand Island, NY), 100 mg/ml primocin
(InvivoGen, San Diego, CA), 2 mM L-glutamine, 2.5% heat-
inactivated defined fetal Bovine Serum (FBS) (both from
ThermoScientific, Logan, UT) and 2.5% NuSerum (BD Biosci-
ences, Bedford, MA). Epithelial cell sheets were separated from
fibroblasts by filtration through a 20-mm mesh filter (Small Parts).
Epithelial cell sheets were retained on the filter, while fibroblasts
passed through. Epithelial cell sheets were recovered by rinsing
and backwashing the filter with complete medium, centrifuged at
5006g for 5 min and analyzed for cell number and viability.
Fibroblasts were centrifuged at 5006g for 10 min and resus-
pended in complete medium and placed in culture as described
below.
Isolation of Vaginal Epithelial Cells
Healthy, premenopausal women (n= 7) were recruited at
Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, New
Hampshire. All volunteers were free of sexually transmitted
infections and were not on any form of chemical or oral birth
control or using an intra-uterine device. Volunteers were provided
with an InStead softcup (menstrual cup) to recover their vaginal
fluid and epithelial cells. The menstrual cup was inserted into the
vagina as per the manufacturer’s instructions for 1 h (http://www.
softcup.com/video-tutorials). Upon removal at DHMC, the cup
was placed in a 50 ml tube and immediately brought to the
laboratory where its contents were centrifuged (8006g for 5 min)
to separate cells and fluid. The cells were cultured in complete
media and assayed for nucleotidases as described below.
Peripheral Blood Mononuclear Cells (PBMC) and CD4+T
Cells
PBMC were isolated by standard Ficoll density gradient
centrifugation. CD4+T cells were purified from PBMC using
magnetic negative selection with MACS kits (Miltenyi Biotech,
Auburn, CA) and incubated in 6-well plates (Corning, Corning,
NY) with X-VIVO 15 Media (Lonza, Walkersville,MD) supple-
mented with 10% human AB serum (Valley Biomedical,
Winchester, VA). Purity higher than 98% was obtained for
CD4+T cell populations after magnetic isolation (data not shown).
Cell Incubation
Epithelial cell culture. To establish a cell culture system of
polarized human FRT epithelial cells with both apical and
basolateral compartments, FRT epithelial cells were cultured in
Estradiol Regulation of Nucleotidases
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Matrigel matrix (BD Biosciences) coated Falcon cell culture inserts
in 24-well companion culture plates (Fisher Scientific). Apical and
basolateral compartments contained 300 and 500 ml of complete
medium respectively, which was changed every 2 days. Tight
junction formation of cultured epithelial cell monolayers from FT,
EM and CX was assessed by periodically measuring transepithelial
resistance (TER) using an EVOM electrode and Voltohmmeter
(World Precision Instruments, Sarasota, FL), as described previ-
ously [38–40].
Fibroblast cell culture. Fibroblasts were cultured in T75
flasks (Falcon, Fisher Scientific, Pittsburgh, PA) in complete
medium. The medium was changed every 2 days for 4–6 days to
remove non-adherent cells. Purity was verified by positive
intracellular staining of vimentin and surface expression of
CD90 and lack of CD45 [41,42]. Once stromal fibroblasts
reached confluence, they were trypsinized with 0.05% trypsin-
EDTA (GIBCO, Life Technologies) and seeded into a 24-well
plate at a density of 26105 cells per well in 500 ml complete
medium for at least 48 h prior to treatment.
Vaginal epithelial cell culture. Freshly isolated vaginal
epithelial cells were plated at 16105 cells per well in a 96-well
culture plate (Fisher Scientific, Pittsburgh, PA) in 0.3 mL of
complete media for 24 h prior to treatment.
Endothelial cell culture. Endothelial cells were obtained
from American Type Culture Collection (ATCC; Manassas, VA).
The CRL-1730 human endothelial cell line was cultured in flasks
Figure 2. Effect of estradiol on nucleotidase gene expression in primary uterine endometrial epithelial cells. Fold change in mRNA
expression compared to Control, which was assigned a value of 1 (dashed line), was analyzed by RT-PCR from purified cultures of polarized EM
epithelial cells isolated from 4 patients and treated with estradiol (561028 M) for (A) 2 h or (B) 6 h. NT enzymes are abbreviated as shown in legend
to Figure 1. UD=undetectable. Mean and SEM are shown. *, P,0.05 represents significant difference between control and estradiol treatment for
NT5C1A at 2 h.
doi:10.1371/journal.pone.0069854.g002
Figure 3. Detailed time course for effect of estradiol on NT5C1A and progesterone receptor gene expression in primary uterine
endometrial epithelial cells. Fold change in (A) NT5C1A and (B) progesterone receptor mRNA expression analyzed by RT-PCR compared to
control, which was assigned a value of 1 (dashed line), from purified cultures of polarized EM epithelial cells (patient number 6167) treated with
estradiol (561028 M) over time (30 mins, 1, 2, 4, 6 and 24 h). Mean and SEM are shown from 3 wells at each time point. *, P,0.05 represents
significant difference between control and estradiol treatment.
doi:10.1371/journal.pone.0069854.g003
Estradiol Regulation of Nucleotidases
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using F-12K medium supplemented with heparin, endothelial cell
growth supplement (ATCC) and 10% fetal bovine serum. Primary
human umbilical vein endothelial cells (HUVEC) were cultured in
the same base media but supplemented with Endothelial Cell
Growth Kit containing several growth factors (ATCC). Once
endothelial cells reached confluence, they were trypsinized with
0.05% trypsin-EDTA (GIBCO, Life Technologies) and seeded
into a 24-well plate at a density of 26105 cells per well in 500 ml
complete medium for at least 48 h prior to treatment.
Hormone Preparation
17b-estradiol (Calbiochem, Gibbstown, NJ) and progesterone
(Calbiochem) was dissolved in 100% ethanol for an initial
concentration of 161023 M, evaporated to dryness and suspended
in media containing 10% charcoal dextran-stripped FBS to a
concentration of 161025 M. Further dilutions were made to
achieve final working concentrations of estradiol ranging from
1610211 to 161027 M. Unless otherwise indicated, cells were
treated with 561028 M estradiol and/or 161027 M progester-
one. Both are standard hormone treatment concentrations used by
our laboratory and each is within the physiological range of
hormone concentration [43]. As a control, an equivalent amount
of ethanol without dissolved hormone was initially evaporated.
Cells in culture were switched to media containing charcoal
dextran-stripped FBS prior to hormone treatment. After 24 h, the
media was replaced and cells were treated with hormone. In all
cases, hormone or ethanol control was added to both the apical
and basolateral compartments for epithelial cell cultures and to
plates for all other cells.
TaqMan Real-time RT-PCR
Real-time PT-PCR was done with a two-step protocol as
described previously [44]. Total RNA was isolated from cells using
RNeasy reagent (Qiagen, Valencia, CA) and QIAshredder
columns according to the manufacturer’s recommendations
(Qiagen), and purified on RNeasy columns (Qiagen) with on-
column DNase digestion using the RNase-Free DNase set
(Qiagen). For each specimen, 400 ng of total RNA was reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad)
according to the manufacturer’s recommendations. Relative
mRNA expression levels of genes of interest were measured using
the 59 fluorogenic nuclease assay in real-time quantitative PCR
using TaqMan chemistry on the ABI 7300 Prism real-time PCR
instrument (Applied Biosystems, Carlsbad, CA). The 7 59-
Figure 4. Estradiol effect on nucleotidase NT5C1A gene expression in FRT epithelial cells. Fold change in NT5C1A mRNA expression in
epithelial cells from the (A) EM, n= 9 (B) FT, n = 2 (C) CX, n = 7 and (D) ECX, n = 8, treated with estradiol (561028 M) for 2 (circles) or 4 h (squares).
Control (no estradiol) is assigned a value of 1 (dashed line). n refers to the number of patients for each tissue. Mean and SEM are shown. *, P,0.05
represents significant difference between control and estradiol treatment for NT5C1A.
doi:10.1371/journal.pone.0069854.g004
Estradiol Regulation of Nucleotidases
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69854
Nucleotidases (ID nos. Hs01573922_m1, Hs00261369_m1,
Hs00403674_m1, Hs00366992_m1, Hs00369454_m1,
Hs01105359_g1, Hs00220234_m1,), b-actin (4333762F), OAT
transporters 1 and 3 (Hs00537914_m1 and Hs00188599_m1), and
progesterone receptor (Hs01556702) primer/MGB probe sets
were obtained from Applied Biosystems assays-on-demand. PCR
was conducted using the following cycle parameters: 95uC, 12 min
for 1 cycle (95uC, 20 s; 60uC, 1 min), for 40 cycles. Analysis was
conducted using the sequence detection software supplied with the
ABI 7300. The software calculates the threshold cycle (Ct) for each
reaction and this was used to quantify the amount of starting
template in the reaction. The Ct values for each set of duplicate
reactions were averaged for all subsequent calculations. A
difference in Ct values (DCt) was calculated for each gene by
taking the mean Ct of each gene of interest and subtracting the
mean Ct for the housekeeping gene b-actin for each cDNA
sample. Assuming that each reaction functions at 100% PCR
efficiency, a difference of one Ct represents a 2-fold difference.
Relative expression levels were expressed as a fold-increase in
mRNA expression and calculated using the formula 22DDCt.
Measurement of 59-Nucleotidase Biological Activity Assay
59-nucleotidase biological activity was determined using a 59-
Nucleotidase kit (Diazyme Laboratories, Poway, CA) that was
adapted from a serum to a cellular based assay by modifying the
manufacturer’s protocol. Briefly, estradiol treated- or control-cells
in culture were washed with Hepes Buffered Saline (0.15 M NaCl,
20 mM HEPES, pH7.4). Cells were dislodged with cell stripper
(Cellgro, Manassas, VA), and permalized by incubating cells on ice
5–10 min in Hepes Buffered Saline containing 7.5 mM CHAPS
(Research Organics, Cleveland, OH), followed by gentle pipetting.
After adding reagent buffer to aliquots of permeabilized cells, the
absorbance was monitored at 550 nm (25uC) on a SpectraMax,
M5 (Molecular Devices Corporation, Sunnyvale, CA). Changes in
absorbance were determined at 1 min intervals for ,15 min and
results over a seven-minute interval were averaged once the
baseline had stabilized. A molar extinction coefficient of
18,440 M21 cm21 was used to calculate enzyme activity (1 unit
is equal to the production of 1 mmole of quinone dye/min) and
standards were run with each assay to verify assay linearity.
Sensitivity of this assay is 0.05 mU per million cells.
Statistics
We have evaluated the data using column statistics – one sample
t test, which compares the mean of every column of data to the
hypothetical value (controls are by definition all equal to 1) using
GraphPad Prism 5 (GraphPad Software, San Diego, CA). A p-
value of ,0.05 was taken as indicative of statistical significance.
Results
Human Epithelial Cells from the Upper and Lower FRT
Express 59-Nucleotidase Genes
Epithelial cells from the upper and lower FRT were analyzed
for the gene expression of 59-Nucleotidases by RT-PCR. 59-
Nucleotidases measured were Ecto-59-nucleotidase (NT5E), Cy-
tosolic 59-nucleotidase 1A (NT5C1A), Cytosolic 59-nucleotidase
1B (NT5C1B), Cytosolic 59-nucleotidase II (NT5C2), Cytosolic 59-
nucleotidase III (NT5C3L), Cytosolic 59(39)-deoxyribonucleotidase
(NT5C), and Mitochondrial 59(39)-deoxyribonucleotidase
(NT5M). Total RNA was isolated from FRT cells and mRNA
expression of 59-Nucleotidases was examined by RT-PCR for
quantitative comparison of the relative 59-Nucleotidase expression.
As shown in Figure 1, six out of seven nucleotidase genes
analyzed were found in epithelial cells from the Fallopian tube
(FT), Uterine endometrium (EM), Endocervix (CX), and Ecto-
cervix (ECX). Of those nucleotidases analyzed, only NT5C1B was
undetectable in all samples. When relative expression was
analyzed, NT5E was expressed at the highest concentration in
each cell type with endometrial epithelial cells having the greatest
expression.
Effect of Estradiol on Nucleotidase Gene Expression in
FRT Epithelial Cells
To determine whether estradiol has an effect on nucleotidase
gene expression in primary FRT epithelial cells, polarized cells
were incubated with estradiol (561028 M) for 2, 6 and 24 h. As
seen in Figure 2, estradiol treatment increased the expression of
NT5C1A at 2 h (Figure 2A) but not at 6 h (Figure 2B) in
polarized epithelial cells from 4 patients with no measurable effect
at 24 h (not shown) treatment. Interestingly, of the 7 genes
analyzed, only NT5C1A responded to estradiol treatment with
increased expression. To more fully define the pattern of
nucleotidase expression, a detailed time course study was carried
out in which polarized uterine epithelial cells, from a single patient
(6167EM), were incubated with estradiol for K to 24 h. As seen in
Figure 3A, in a detailed time course study, NT5C1A expression
increased 2.5 fold at 2 h, after which it declined to control values
at 4, 6 and 24 h. Since an increase in progesterone receptor (PR)
expression serves as a positive control for estradiol responsiveness
[45,46], we evaluated PR expression in each of the cell
preparations and found that PR expression increases by more
than 2 fold at 2, 4 and 6 h (Figure 3B).
To determine the extent to which estradiol regulates nucleotid-
ase expression in epithelial cells from the upper and lower FRT,
polarized cells from the EM, FT, CX and ECX were incubated
with E2 for either 2 or 4 h prior to analysis of all 7 nucleotidase
genes. As shown in Figure 4A, in 9 patients, estradiol significantly
increased NT5C1A expression in EM epithelial cells at 2 h (n= 4)
or 4 h (n= 5), with only 1 cell preparation showing stimulation at
Figure 5. Estradiol has a dose-dependent effect on NT5C1A
gene expression in primary uterine endometrial epithelial
cells. Fold change in NT5C1A mRNA expression analyzed by RT-PCR
from purified cultures of polarized EM epithelial cells (patient number
6157) treated with increasing doses of estradiol (from 1610211 M up to
161027 M) for 2 h. Control (no estradiol) is assigned a value of 1
(dashed line). The mean and SEM from triplicate cultures are shown. *,
P,0.05 represents significant difference between control and estradiol
treatment.
doi:10.1371/journal.pone.0069854.g005
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both 2 and 4 h. In contrast to NT5C1A in the EM, we
unexpectedly found that under identical incubation conditions,
estradiol had no effect on gene expression of NT5C1A in epithelial
cells from the FT (Figure 4B), CX (Figure 4C) or ECX
(Figure 4D) at either 2 or 4 h. Further analysis of epithelial cells
from FT, CX and ECX in time course studies (1–24 h) failed to
show any evidence of an estradiol effect on nucleotidase gene
expression on any of the 7 genes analyzed (data not shown).
Given that estradiol levels in blood vary with stage of the
menstrual cycle [43], we carried out a dose response experiment
with EM epithelial cells from a single tissue (6157EM) at
concentrations ranging from 1610211 M to 161027 M for 2 h.
As seen in Figure 5, estradiol had a stimulatory effect on
NT5C1A gene expression (greater than 2-fold increase) in primary
endometrium epithelial cells at doses ranging from 1610210 M to
161027 M. The higher concentrations are the same concentra-
tions at which the estrogen receptor is saturated [47].
Nucleotidase Gene Expression in FRT Fibroblasts
To determine whether underlying stromal fibroblasts from the
upper and lower tract also express 59-Nucleotidases, fibroblasts
were isolated from FRT tissues and grown to confluence prior to
analysis. Verification of cell purity was confirmed by flow
cytometric staining (data not shown). Following the same
procedure described above for RNA isolation and analysis of 59-
Nucleotidase genes, we found a profile of expression similar to that
seen with epithelial cells. As seen in Figure 6, fibroblast
expression of NT5E was significantly higher than any other gene
analyzed. Interestingly, similar to that seen with epithelial cells
(Figure 1), the second highest level of expression was NT5C2,
with NT5C1B not detected in any of the 2 to 7 specimens
analyzed. To evaluate whether estradiol alters nucleotidase
mRNA expression, purified fibroblasts from the Fallopian tubes,
uterus, endocervix and ectocervix were incubated with estradiol
(561028 M) for 2, 4, 6 and 24 h after which gene expression was
analyzed. Irrespective of the time in culture, we found in 6–8
fibroblasts preparations, each from different patients, that estradiol
had no significant effect on any of the genes expressed at any of the
four sites (data not shown).
Figure 6. Relative gene expression of nucleotidases in FRT fibroblasts. Data is shown as the ratio of the nucleotidase (NT) gene expression
to the expression of b-actin. Purified cultures of fibroblasts from (A) FT n= 2, (B) EM n= 7, (C) CX n=6 and (D) ECX n=5 were analyzed for changes in
nucleotidase gene expression by RT-PCR. n refers to the number of patients. UD=undetectable. The mean and SEM are shown.
doi:10.1371/journal.pone.0069854.g006
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Nucleotidase and OAT Transporter Gene Expression in
Vaginal Epithelial Cells, Blood CD4+T cells and
Endothelial Cells
Vaginal epithelial cells. Owing to the development of a
protocol for isolating mRNA from vaginal epithelial cells, we have
analyzed these cells for nucleotidase gene expression. Surprisingly,
of the nucleotidase genes tested, only NT5C2 is expressed in
squamous epithelial cells (data not shown). This is in contrast to
epithelial cells from the FT, EM, CX and ECX, which expressed
6/7 of the genes analyzed.
CD4+T cells. Recognizing that the first cells to be protected
by vaginal microbicides and most likely infected by HIV are
CD4+T cells [48], we isolated purified blood CD4+T cells by
magnetic bead separation prior to measuring nucleotidase gene
expression. As shown in Figure 7A, in contrast to epithelial cells
and fibroblasts, NT5C2 expression was greater than all other
genes analyzed followed by NT5C3L and NT5C and NT5E.
Interestingly, when relative expression of CD4+T cells was
compared to that measured in epithelial cells and fibroblasts (not
shown), all genes measured were 2–10 fold lower than that seen in
cells from the FRT. Similar to our findings with fibroblasts,
incubation of CD4+T cells with estradiol for 2, 6, or 24 h
(Figures 7B–D), had no effect on nucleotidase gene expression.
Endothelial cells. Under conditions of oral ingestion of
microbicides [48], TFV traverses and/or passes through endothe-
lial cells to reach underlying immune cells in the FRT. To assess
the extent to which estradiol regulates nucleotidase gene
expression in endothelial cells, we analyzed two endothelial cell
preparations. HUVEC cells were used in these studies in lieu of
endothelial cells from FRT tissues, which are limited by the
number of cells present in our tissue specimens. Irrespective of
whether we analyzed primary HUVEC cells or the HUVEC cell
line, we found that whereas epithelial cells and fibroblasts express
6/7 nucleotidase genes (Figures 1 and 6), HUVEC cells express
5/7 nucleotidase genes including NT5E, NT5C2, NT5C3L
NT5C and NT5M. Interestingly, expression was significantly
lower (approximately 10-fold) in HUVEC cells when compared to
epithelial cells and fibroblasts (data not shown). To determine
whether any of these genes were responsive to estradiol treatment,
detailed time course studies (1–24 h) were carried out. Irrespective
of the length of incubation and whether the primary or cell line
were grown on inserts or plastic, estradiol had no effect on
nucleotidase gene expression.
Figure 7. Effect of estradiol on nucleotidase gene expression in resting blood-derived CD4+T cells. (A) Relative gene expression of
nucleotidases in blood-derived CD4+T Cells derived from 6 donors. Data is shown as the ratio of the nucleotidase (NT) gene expression to the
expression of b-actin. (B–D) Effect of estradiol treatment on fold change in mRNA expression in CD4+T cells treated with 561028 M estradiol for (B) 2,
(C) 6 and (D) 24 h. Control (no estradiol) is assigned a value of 1 (dashed line). UD=undetectable. The mean and SEM from 6 donors are shown.
doi:10.1371/journal.pone.0069854.g007
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OAT1 and OAT3 transporters. In related studies, we
determined that both sets of HUVEC cells as well as CD4+T
cells, did not express the transporters OAT1 and OAT3 that
would transport the microbicide into endothelial cells (data not
shown), indicating that tenofovir enters tissues by other means
than through endothelial cells in tissues. Similarly, neither the
epithelial cells nor the fibroblasts from throughout the FRT
expressed the genes for OAT1 and OAT3 (data not shown).
Nucleotidase Biological Activity in FRT Epithelial Cells and
Fibroblasts
59-Nucleotidase, assayed as 59-AMPase, has been extensively
characterized and established as a stable, quantitative plasma
membrane marker in blood cells as well as HeLa S3 cells [49]. To
measure 59-Nucleotidase biological activity in FRT cells, we
adapted the Diazyme 59-Nucleotidase assay from a serum to a
cellular based assay to measure 59-Nucleotidase biological activity
in isolated epithelial cells and stromal fibroblasts from throughout
the FRT. It is important to note that Nucleotidase biological
activity, as measured by our modified assay, readily detects those
nucleotidases that prefer purine-based substrates. These nucleo-
tidases, which are thought to be involved in TFV-DP metabolism
include NT5E, NT5C1A, and NT5C2. Nucleotidases with a
preference for pyrimidine bases such as NT5C, NT5C3L, and
NT5M would show very little activity with this assay. Following
optimization of this assay in terms of cell numbers for each cell
type, we evaluated nucleotidase activity in isolated cells and
compared activity to that seen in PBMC and CD4+T cells isolated
from blood. As seen in Figure 8, when 59-Nucleotidase activity
was measured, activity in epithelial cells and fibroblasts, but not
PBMC or CD4+T cells, was measureable in cells from 3–5 FRT
tissues. Interestingly, under conditions in which cell numbers were
maximized to measure activity, biological activity was detected in
purified CD4+T cells (data not shown). Moreover, we found that
biological activity varies with the site analyzed. For examples, we
found that activity tended to be greater in CX epithelial cells
compared to that of EM or ECX epithelial cells. In contrast, the
activity in fibroblasts was similar irrespective of whether cells were
from the EM, CX and ECX.
Effect of Estradiol on Nucleotidase Biological Activity in
FRT Epithelial Cells and Fibroblasts
To determine whether estradiol had an effect on 59-Nucleotid-
ase biological activity in primary FRT epithelial cells, cells were
incubated with estradiol (561028 M) for 24 h. As shown in
Figure 9, when control values from 3–5 patients are normalized
to 1.0, we found that E2 treatment of primary epithelial cells from
the EM, CX and ECX significantly increased the 59-nucleotidase
biological activity by 30–70% at 24 h. To determine whether this
effect persists in culture, EM cells were incubated with estradiol for
48 h prior to measurement of nucleotidase activity. We found that
estradiol increases in expression at 48 h beyond that seen at 24 h
(data not shown). Our findings of increased nucleotidase biological
activity in epithelial cells are different from our mRNA gene
expression findings for EM, CX and ECX epithelial cells. In
contrast to EM epithelial cells, in which both biological activity
and nucleotidase mRNA expression increased in response to
estradiol (Figures 2, 3, 4, 5, 9), CX and ECX epithelial cell
increases in biological activity occurred in response to estradiol
despite the fact that we were unable to detect significant changes in
mRNA nucleotidase expression. The apparent disconnect between
gene expression fluctuations within 2–4 h and biological activity
elevations at 24–48 hours may be due to cumulative expression of
these genes, which results in an increase in biological activity.
In order to evaluate whether fibroblasts from the FRT are
responsive to estradiol, isolated cells were incubated with estradiol
for either 24 or 48 h prior to measurement of 59-Nucleotidase
biological activity. As shown in Figure 10, we found that
fibroblasts from the EM, CX and ECX were hormonally
responsive in that estradiol had a 24 h stimulatory effect on
nucleotidase biological activity in EM and CX fibroblasts, as well
as a 48 h increase in ECX fibroblasts. While responsiveness was
Figure 8. 59-Nucleotidase biological activity in epithelial cells
and fibroblasts from the FRT, peripheral blood mononuclear
cells (PBMC) and blood-derived CD4+T cells. 59-nucleotidase
biological activity was measured by a modified Diazyme 59-nucleotidase
assay in purified cultures of epithelial cells and fibroblasts from the EM,
CX, and ECX as well as PBMC and CD4+T cells. Each circle represents
tissue from an individual patient or donor. Values are expressed as milli
Enzyme Units (mEU) per million cells. The mean and SEM are shown.
UD=undetectable. Sensitivity of this biological activity assay is 0.05 mU
per million cells.
doi:10.1371/journal.pone.0069854.g008
Figure 9. Effect of estradiol on 59-nucleotidase biological
activity in primary endometrial, endocervix and ectocervix
epithelial cells. 59-Nucleotidase biological activity was measured by a
modified Diazyme 59-Nucleotidase assay in purified cultures of EM, CX
and ECX epithelial cells treated with estradiol (561028 M) for 24 h. Data
were normalized to control values, dashed line indicates an assigned
value of 1. Each circle represents a different patient. The mean and SEM
are shown. *, P,0.05 represents a significant difference between
estradiol treatment and control.
doi:10.1371/journal.pone.0069854.g009
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more variable with time of incubation than that seen with
epithelial cells, a stimulatory effect was seen in fibroblasts from
each of 4–6 patients. This finding of increased biological activity
was unexpected in light of our inability to measure changes in
nucleotidase mRNA expression in response to hormone treatment.
Recognizing that progesterone is an important hormone present
during the secretory phase of the menstrual cycle, we asked if
progesterone alone and in combination with estradiol had any
effect on 59-Nucleotidase biological activity. In studies with
epithelial cells and fibroblasts, we failed to observe any consistent
response to progesterone alone or in combination with estradiol
(data not shown). Similar findings were reported previously using
histological staining of epithelial cells for nucleotidase enzyme
[23].
Nucleotidase Biological Activity in Blood CD4+T cells and
Endothelial Cells
To determine whether CD4+T cell and HUVEC cell nucleo-
tidase biological activity is altered by hormone treatment, cells
were analyzed as described above following incubation with
estradiol for 24 and 48 h. In several experiments in which the
number of CD4+T cells was increased, biological activity was too
low to measure with our assay. In contrast, when HUVEC cells
were analyzed, nucleotidase activity was detectable and unaffected
by estradiol treatment (not shown). Interestingly, HUVEC
nucleotidase biological activity was approximately 5-fold less that
that seen in epithelial cells and 2-fold less that measured in
fibroblasts. Overall these results suggest that nucleotidase activity
in endothelial cells is not hormonally regulated and unlikely to
influence the metabolism of TFV in FRT tissues. Further studies
are needed to determine whether estradiol regulates purified blood
CD4+T cells metabolism of TFV-DP.
Discussion
Tenofovir, either orally or applied locally to the vagina in gel
form, has gained credence, albeit with some caveats, for the
prevention of HIV infection in women [7,48,50–52]. To
determine if sex hormones influence the expression and biological
activity of enzymes that alter TFV metabolism, we evaluated the
effect of estradiol on expression of NT gene expression and NT
biological activity in purified human FRT epithelial cells and
fibroblasts and found that FRT epithelial cells and fibroblasts from
the FT, EM, CX and ECX express NT that are biologically active.
Unlike epithelial cells from other FRT sites, estradiol increased
NT gene expression in EM epithelial cells, but not epithelial cells
or fibroblasts from other FRT sites. Using a biological assay for
nucleotidases, estradiol increased NT activity of EM, CX and
ECX epithelial cells and fibroblasts but had no effect on primary
endothelial cells, an endothelial cell line, or blood CD4+T cells.
Overall, these studies demonstrate that estradiol has a stimulatory
effect on NT gene expression and/or biological activity in FRT
epithelial cells and fibroblasts.
Nucleotidase biological activity as measured by our modified
assay does not detect all of the different nucleotidase forms equally
but readily detects nucleotidases such as NT5E, NT5C1A, and
NT5C2 that prefer purine based substrates and would be expected
to be involved in TFV-DP metabolism. Nucleotidases with a
preference for pyrimidine bases such as NT5C, NT5C3L, and
NT5M show very little activity with this assay. Our findings
demonstrate that NT5E as well as 5 other nucleotidases are highly
expressed in epithelial cells and fibroblasts, which make up the
majority of cells in FRT tissues [53].
Our results demonstrate that estradiol increases both 59NT
nucleotidase biological activity and gene expression in EM
epithelial cells. In contrast, estradiol increased 59-NT biological
activity in CX and ECX epithelial cells as well as EM, CX and
ECX fibroblasts, but had no effect on 59NT gene expression. One
explanation for the apparent disconnect between gene expression
and biological activity may be the cutoff for significance in the data
presented. In previous studies, in which we measured FRT gene
expression in FRT tissues from different individuals, we used a 2-
fold change as a minimum for reporting significant differences
[54]. In contrast, others have used less stringent conditions (1.5-
fold), which magnifies differences seen in response to hormone
treatment [55]. Using 1.5-fold, we found that a number of NT
genes appear to increase (data not shown), but given the
background expression and patient-to-patient variability we have
Figure 10. Effect of estradiol on 59-nucleotidase biological activity in primary endometrial, endocervix and ectocervix fibroblasts.
59-Nucleotidase biological activity was measured by a modified Diazyme 59-Nucleotidase assay in purified fibroblasts. EM, CX and ECX fibroblasts
were treated with estradiol (561028 M) for (A) 24 and (B) 48 h. Data were normalized to control values, dashed line indicates an assigned value of 1.
Each dot represents a different patient. The mean and SEM are shown. *, P,0.05 represents a significant difference between control and estradiol
treatment at either 24 or 48 h.
doi:10.1371/journal.pone.0069854.g010
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reported these findings as not significant. Thus the cumulative
expression of these genes might result in an increase in biological
activity. What is clear from our uterine epithelial mRNA studies is
that responsiveness to estradiol is rapid and transient (2 and 4 h).
An alternative explanation is that despite our attempts to measure
changes in nucleotidase activity, the time intervals selected may
have been inadequate to detect transient changes in expression.
Alternatively, since Christensen reported a lack of correlation
between CD73 gene expression and ecto-59nucleotidase bioactiv-
ity in blood mononuclear cells [56], her findings along with ours
suggest that post-transcriptional mechanisms may be involved.
Our studies suggest that hormone regulation of endothelial cell
nucleotidase mRNA and biological activity are unlikely to play a
role in TFV metabolism to immune cells in the FRT. In addition
to finding that nucleotidase gene expression in endothelial cells
(primary and cell line) are lower (approximately 3-fold) than that
seen in FRT epithelial cells and fibroblasts, under no conditions
were we able to measure estradiol changes in nucleotidase mRNA
expression or biological activity. Just why gene expression and
biological activity were so low in our studies of endothelial cells is
unclear. Endothelial cells are known to express NT5E that are
stimulated by LPS [57] and inhibited by TNF-a [58]. It may be
that under our culture conditions, endothelial cells are either not
stimulated or that nucleotidase gene expression is negatively
regulated and therefore express low levels of nucleotidases. Since
endothelial cells are hormonally responsive [59], the failure of
estradiol to modulate nucleotidase gene expression in the
endothelial cells suggests that these genes may not be regulated
in these cells. Alternatively, the lack of an estrogen effect on
nucleotidases may be associated with the estrogen receptor profile
since endothelial cells have ERb and lack ERa [60]. Since these
receptors have unique functions, it is possible that expression is not
efficiently regulated through the ERb system. Similar to endothe-
lial cells, we found that NT mRNA expression in CD4+T cells was
very low relative to FRT epithelial cells and fibroblasts and
unresponsive to estradiol. Moreover, we found that we were
unable to measure biological activity, under circumstances in
which we know these cells are hormonally responsive to estradiol.
Given the importance of the menstrual cycle in gene expression,
we asked whether estradiol, which peaks in blood at midway
through the menstrual cycle [19], might influence the expression
and biological activity of enzymes that alter TFV metabolism in
the FRT. Others have shown that following entry by diffusion into
cell, TFV is metabolized to TFV-DP, the active form that inhibits
HIV reverse transcriptase [48,51]. Our findings that estradiol
increases NT biological activity in epithelial cells and fibroblasts
suggest that TFV-DP could be converted back to TFV and diffuse
or be transported out of these cells, thus making more TFV
available for uptake by HIV-target cells. In the absence of
estradiol, TFV-DP would be retained in epithelial cells and
fibroblasts, which make up the majority of cells in the FRT. Under
these conditions, we postulate that less TFV would be available for
HIV-target cells protection. Whether epithelial cells and fibro-
blasts act as a reservoir for TFV that can provide microbicide to
HIV-target cells in response to estradiol stimulation remains to be
determined. Future studies of TFV metabolism are needed to
determine whether changes of estradiol levels during the menstrual
cycle influence microbicide protection against HIV infection
during the menstrual cycle. Finally, whereas nucleotidase expres-
sion and bioactivity suggest a potential estradiol-induced effect on
catabolism, metabolism of microbicides is an admixture of
anabolic and catabolic events, both of which need to be addressed
in future studies.
We previously hypothesized that women are most susceptible to
HIV infection when estradiol levels are highest during the
menstrual cycle [19]. This is due to estradiol suppression of
specific immune mechanisms in the FRT designed to maximize
the success of reproduction. Our finding that estradiol enhances
NT biological activity in epithelial cells and fibroblasts suggests
that HIV-target cells (CD4+T cells and macrophages) would be
better protected at midcycle and during the early secretory stage of
the menstrual cycle. These findings have major implications in
that it would theoretically close the ‘‘Window of Vulnerability’’ in
women using oral and topical PrEP. Of equal importance is the
impact of chemical contraceptives on microbicide metabolism. In
studies to determine TFV and TFV-DP concentrations in blood
and blood PBMC, Coleman et al. found that the use of hormonal
contraception (oral and injectable) was associated with decreased
serum and intracellular PBMC TFV concentrations [61]. Since as
many as 70% of women in TFV PrEP trials are using some form of
chemical contraception, our findings that estradiol alters NT
biological activity in cells from the FRT, when considered along
with those of Coleman et al., provides compelling evidence that
studies including microbicide trials are needed to determine the
extent to which tissue in the FRT changes with stage of the
menstrual cycle and hormonal contraceptive use.
Beyond its effects on TFV, our findings suggest that estradiol
stimulation of NT activity in the human FRT may profoundly
alter adenosine metabolism in FRT tissues. Adenosine is a
significant signal molecule involved in a variety of physiological
functions [62], many of which involve immune regulation [63].
For example, in neutrophils, ecto-59-nucleotidase mediates the
conversion of neutrophil-derived adenosine monophosphate to
adenosine which promotes endothelial barrier function [64]. Also,
in conjunction with CD39, which is an endothelial ecto-nucleoside
triphosphate diphosphohydrolase (NTPDase), ecto-59-nucleotidase
produces extracellular adenosine, which affects neutrophil, mac-
rophage and dendritic cell function [63]. Ecto-59-nucleotidase is
up-regulated by TGFb in CD8+T cells, DCs and macrophages
[65], and has been implicated in immunosuppression caused by T-
regs [66,67], macrophage activation [68], mucosal inflammation
as well as Th17 immunosuppressive activity [69]. Other studies
have shown that the CD39/adenosine axis is involved in T-reg
suppression in HIV infection [67]. Additional studies are needed
to examine the extent to which estradiol regulates adenosine
modulation of immune protection against HIV infection.
In conclusion, these studies demonstrate that estradiol regulates
NT expression and biological activity in epithelial cells and
fibroblasts from the upper and lower FRT, but not in endothelial
cells or blood CD4+T cells. Future studies are needed to evaluate
the effects of sex hormones and chemical contraceptives on
microbicide concentrations in FRT tissues as they relate to PrEP
trial outcomes, to more fully define the complex interactions of the
endocrine system and its influence on microbicide efficacy and
protection against HIV.
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